91 related articles for article (PubMed ID: 18314916)
21. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
22. [Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
Hansen PB; Hasselbalch HC
Ugeskr Laeger; 2004 Feb; 166(6):466-9. PubMed ID: 15045710
[No Abstract] [Full Text] [Related]
23. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
[TBL] [Abstract][Full Text] [Related]
24. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
Roll P; Dörner T; Tony HP
Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
[TBL] [Abstract][Full Text] [Related]
27. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
[TBL] [Abstract][Full Text] [Related]
28. New treatment options for immune-mediated hematological disorders.
Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
[TBL] [Abstract][Full Text] [Related]
29. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
[TBL] [Abstract][Full Text] [Related]
30. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
[TBL] [Abstract][Full Text] [Related]
31. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
Pro B; Leber B; Smith M; Fayad L; Romaguera J; Hagemeister F; Rodriguez A; McLaughlin P; Samaniego F; Zwiebel J; Lopez A; Kwak L; Younes A
Br J Haematol; 2008 Nov; 143(3):355-60. PubMed ID: 18764869
[TBL] [Abstract][Full Text] [Related]
32. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
34. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
35. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
36. Durable responses to rituximab in acquired factor VIII deficiency.
Singh AG; Hamarneh IS; Karwal MW; Lentz SR
Thromb Haemost; 2011 Jul; 106(1):172-4. PubMed ID: 21544323
[No Abstract] [Full Text] [Related]
37. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
38. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
39. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
